Karyopharm Therapeutics | KPTI - Passivo Circulante





Passivo Circulante Alterar Data
AbbVie USD 41.64B 458M 2026-06
Abbott USD 18.38B 1.88B 2026-03
Amgen USD 25.5B 547M 2026-06
AstraZeneca USD 31.55B 1.02B 2026-06
BioCryst Pharmaceuticals USD 208.85M 13.46M 2026-06
Bristol-Myers Squibb USD 18.66B 499M 2026-06
Eli Lilly USD 47.74B 11.11B 2026-06
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
GlaxoSmithKline GBP 21.53B 895M 2026-06
Incyte USD 1.31B 177.55M 2026-06
J&J USD 54.9B 2.82B 2026-06
Karyopharm Therapeutics USD 117.3M 25.24M 2026-03
MacroGenics USD 95.94M 52.82M 2026-03
Merck USD 27.73B 786M 2026-06
Nektar Therapeutics USD 57.71M 4.17M 2026-03
Novartis USD 31.75B 374M 2026-06
Novartis USD 31.37B 4.1B 2026-03
Pfizer USD 32.65B 1.7B 2026-06
Regeneron Pharmaceuticals USD 5.53B 422.9M 2026-06
Roche Holding CHF 28.85B 846M 2026-06
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Takeda JPY 2.76T 335.02B 2026-06
Tectonic Therapeutic USD 12.96M 3.29M 2026-03
TG Therapeutics USD 268.49M 81.38M 2026-06
Ultragenyx Pharmaceutical USD 351M 26M 2026-06
Xencor USD 81.86M 8.41M 2026-06